Medical/Pharmaceuticals

Catalent Debuts New Corporate Brand, Elevating Customer Service Excellence by "Championing the Missions that Matter™"

TAMPA, Fla., Oct. 31, 2025 /PRNewswire/ -- Catalent, Inc., a leading global contract development and manufacturing organization, today unveiled its new corporate brand, marking a strategic evolution that underscores the company's commitment to delivering unparalleled customer service and its focu...

2025-10-31 08:30 1475

NovaBridge Subsidiary Visara Assigns Its Exclusive License to Everest Medicines for VIS-101 in Greater China and Certain Other Asian Countries

* NovaBridge subsidiary Visara assigned its exclusive license to Everest Medicines to accelerate the development of potential best-in-class therapy for wet AMD, VIS-101, leveraging Everest Medicines' strong clinical and commercialization expertise inGreater China and other Asian markets * Nov...

2025-10-30 16:15 1337

U.S. FDA grants interchangeability designation to Celltrion's denosumab biosimilars, STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo)

* The U.S. FDA approved STOBOCLO® (denosumab-bmwo) and OSENVELT®  (denosumab-bmwo) as interchangeable with the reference products PROLIA® (denosumab) and XGEVA® (denosumab), respectively, for all approved indications, effective as ofOctober 29, 2025 * The interchangeability (IC) designations o...

2025-10-30 15:28 2232

United Imaging Healthcare Q3 2025 Results: In The First Three Quarters Of 2025, Overseas Revenue Up 42% YoY

SHANGHAI, Oct. 30, 2025 /PRNewswire/ -- United Imaging Healthcare (SSE: 688271), a global leader in advanced medical imaging and radiotherapy equipment, has released its financial results for the first three quarters of 2025, showcasing robust financial performance. During this period, the compa...

2025-10-30 13:58 1352

Everest Medicines Acquires Exclusive Greater China and Other Asian Country Rights to VIS-101, a Novel Bifunctional Biologic for Serious Eye Disorders

* Everest Medicines acquired an exclusive license to develop, manufacture, and commercialize VIS-101 inGreater China, Singapore, South Korea, and certain Southeast Asian countries. * Under the assigned exclusive license, Everest Medicines will make an upfront payment ofUS$7 million (equivalen...

2025-10-30 11:05 1753

LOTTE BIOLOGICS and SK pharmteco Sign Strategic Partnership to Strengthen Global ADC CDMO Capabilities

* Two global CDMO leaders have joined forces to strengthen their presence in the rapidly growing antibody-drug conjugate (ADC) market. * The collaboration will deliver integrated, one-stop CDMO services spanning antibody drug substance, linker–payload production, and bioconjugation, supported...

2025-10-30 09:15 3107

Jenscare released its multi-product portfolio's, including LuX-Valve Plus TRINITY study, JensClip and Ken-Valve, remarkable clinical outcomes at TCT 2025 in the U.S.

BEIJING, Oct. 29, 2025 /PRNewswire/ -- Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company, recently released 6-month follow-up results of TRINITY Trial of LuX-Valve Plus, a promising self-developed TTVR system, and 1-year outcomes and c...

2025-10-30 09:00 1269

ArkBio Initiates Phase II Clinical Trial of AK0610, a Preventive Monoclonal Antibody for Respiratory Syncytial Virus Infection

SHANGHAI, Oct. 30, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announcedthe initiation of a Phase II clinical study of AK0610, a fully human monoclonal antibody designed to prevent respiratory syncytial virus (RSV) infection. Building on ArkBio's previous experi...

2025-10-30 09:00 1842

Ascletis Selects a Best-in-Class Once-Monthly Subcutaneously Administered Amylin Receptor Agonist, ASC36, for Clinical Development

-In head-to-head non-human primate (NHP) studies, average observed half-life of ASC36 was approximately15 days, 3-fold longer than petrelintide, which supports once-monthly subcutaneous (SQ) dosing in humans. -ASC36 demonstrated approximately 91% greater relative body weight reduction compared t...

2025-10-30 08:10 1574

Jungbunzlauer Tricalcium Citrate Excipient Demonstrates Outstanding Results in Direct Compression Study

- New research confirms Jungbunzlauer's TCC TB supports efficient, high-quality tablet manufacturing across challenging pharmaceutical and nutraceutical applications - BASEL, Switzerland, Oct. 29, 2025 /PRNewswire/ -- Jungbunzlauer, a global leader in high-quality, sustainable ingredients, and P...

2025-10-29 23:21 1632

I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform

* New corporate brand reflects strategic transformation to a global biotech platform accelerating access to innovative medicines for patients worldwide * Strategy centers on broadening access to global capital and innovation through a plannedHong Kong initial public offering (IPO), and holding...

2025-10-29 23:15 2891

Suvoda launches unified patient app to reduce logistical challenges for clinical trial participants

CONSHOHOCKEN, Pa., Oct. 29, 2025 /PRNewswire/ -- Suvoda  (recently merged under common ownership with Greenphire), a global clinical trial technology company specializing in software s...

2025-10-29 21:15 1279

Study Finds ELISAs in Milk Samples Less Reliable for Johne's Disease Detection -- $198M in Dairy Losses Underscore Need for More Accurate Milk Testing

Peer-reviewed (in-press) study finds serum-based antibody tests align, but milk results vary—calling for improved milk-specific diagnostics to strengthen herd surveillance and profitability CARLSBAD, Calif., Oct. 29, 2025 /PRNewswire/ -- Pictor Holdings Inc. today announced new peer-reviewed dat...

2025-10-29 21:00 1352

ICHORtec and Johns Hopkins University Expand Collaboration to Enhance CRISPR Gene Editing Specificity Using Quantum FMB® Technology

BERLIN and BALTIMORE, Oct. 29, 2025 /PRNewswire/ -- ICHORtec GmbH is pleased to announce an expanded research collaboration with the laboratory of Professor Gregory A. Newby in the Department of Genetic Medicine at the Johns Hopkins University School of Medicine. This partnership, aligned with the...

2025-10-29 21:00 1448

"World Hair Transplant Repair Day" Taking Place on 11/11 Shines Light on Proliferation, Dangers of Black-Market Hair Transplant Clinics Worldwide

ISHRS Hosts Live Surgery Workshop in Bucharest, Romania, November 7-9, 2025, focusing on hair repair CHICAGO, Oct. 29, 2025 /PRNewswire/ -- According to a recent member survey

2025-10-29 20:11 1188

IASO Bio Partners with Korea's GC Cell to Bring CAR-T Therapy to Korea

* Potential new treatment option for multiple myeloma patients in Korea. * Expanded patient access through competitive pricing. SHANGHAI and NANJING, China and PLEASANTON, Calif., Oct. 29, 2025 /PRNewswire/ -- Nanjing IASO Biotechnology ("IASO Bio"), today announced that it has signed an agree...

2025-10-29 17:01 1096

/C O R R E C T I O N -- GSK/

In the news release, Five social service agencies join Singapore's shingles awareness movement, issued29-Oct-2025 by GSK over PR Newswire, we are advised by the company that the one of the community partner's name, should read "Lions Befrienders" rather than "Lion Befrienders" as originally issue...

2025-10-29 16:59 1354

What Hebei Can Offer丨Biomedicine and Beyond

SHIJIAZHUANG, China, Oct. 29, 2025 /PRNewswire/ -- A News Report from Great Wall New Media -- Among Hebei Province's 107 key specialized industrial clusters, the biopharmaceutical cluster in Shijiazhuang High-Tech Zone has emerged as a model of high-quality development and a key engine drivingHeb...

2025-10-29 15:23 1342

Total Investment of Approx. USD 11.6 Million in TB and NTD R&D Projects With Partners Including Fujifilm, Stop TB Partnership, and the Ohio State University

TOKYO, Oct. 29, 2025 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximatelyJPY 1.73 billion (USD 11.6 million1) in four R&D projects for the development of diagnostics and a vaccine for tuberculosis (TB), neglected tropical diseases...

2025-10-29 10:00 1154

VUNO Partners with European Firms to Advance DeepCARS® Market Entry in Europe

- Strategic MOU enhances market access and extends reach to over 900 hospitals across the region SEOUL, South Korea, Oct. 28, 2025 /PRNewswire/ -- VUNO Inc., a global medical AI company, announced today that it has signed a strategic Memorandum of Understanding (MOU) with Contextflow, an Austria...

2025-10-29 09:14 1350
1 ... 36373839404142 ... 644

Week's Top Stories